The Kinase Binding Buffer is a spare part intended for use in the HTRF® Kinase Binding platform only.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Biochemical Enzymatic Assay |
The Kinase Binding Buffer is a spare part intended for use in the HTRF® Kinase Binding platform only.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
The Kinase Binding Buffer is used to perform saturation binding (Kd-determination) and/or competitive binding assays within the HTRF® Kinase Binding platform only.
Application |
Biochemical Enzymatic Assay
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Buffer
|
Shipping Conditions |
Shipped Ambient
|
Target Class |
Kinases
|
Technology |
TR-FRET
|
Therapeutic Area |
Metabolism/Diabetes
Neuroscience
Oncology & Inflammation
|
Unit Size |
20 ml
|
The binding of a fluorescent tracer is detected in a sandwich assay format using either a specific Anti-GST, 6HIS antibody or Streptavidin labeled with Europium Cryptate (donor), which bind to the tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more tracer, and will saturate depending on the dissociation constant (Kd ) of the tracer to the tagged kinase. When an inhibitor of the kinase is added, the tracer will be displaced and the HTRF signal will disappear, depending on the dose.
Pharmacological evaluation of inhibitors of interest can be run in 96- or 384-well plates.
First, a dilution series of inhibitor ranging between 40 µM and 0.23 nM is prepared, and 5 µL of each concentration are dispensed into the plate. Next, 5 µL of tagged-Kinase are added, followed by 5 µL of anti-tag Eu-cryptate. Finally, 5 µL of tracer solution are added, prepared at 4x the final concentration. The HTRF ratio is measured after 1 H of incubation.
Analyses of the data give typical dose response curves ranging between 10 µM and 56 pM, enabling an evaluation of the IC50/Ki values for the inhibitor of interest.
Are you looking for resources, click on the resource type to explore further.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
HTRF assays to assess PROTAC® compounds
Kinases constitute about 2% of all human genes and are essential proteins involved in...
Get up to speed with the latest developments on PROTAC® design and verification.
Harnessing the power of the cellular protein and...
A BRD4 Case Study
BRD4 is involved in gene transcription and is frequently dysregulated in many types of cancer. It is one of the...
We are here to answer your questions.